Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shibu Thomas

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 26, 2024
Characterization of FGFR Alterations and Activation in Patients with High-Risk Non-Muscle-Invasive Bladder CancerJoel R Eisner, Florus C de Jong, Yoichiro Shibata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2016
Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived XenograftsHung-Ming Lam, Ryan McMullin, Holly M Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2021
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic DiseaseMatthew R Smith, Shibu Thomas, Michael Gormley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 26, 2022
Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trialPeter J Hoskin, Kirsten Hopkins, Vivek Misra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 29, 2025
Erdafitinib in Patients with FGFR-altered Advanced or Metastatic CholangiocarcinomaShubham Pant, Joon Oh Park, Wu-Chou Su, et al.
The Lancet. Oncology|October 3, 2021
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 studyFred Saad, Eleni Efstathiou, Gerhardt Attard, et al.
JAMA|December 4, 2019
Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical TrialPeter J Hoskin, Kirsten Hopkins, Vivek Misra, et al.
The Lancet. Oncology|August 4, 2023
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Martin Schuler, Gopa Iyer, et al.
Anti-Cancer Agents in Medicinal Chemistry|August 31, 2012
Selected approaches for rational drug design and high throughput screening to identify anti-cancer moleculesMichael Hedvat, Luni Emdad, Swadesh K Das, et al.
JCO Precision Oncology|September 14, 2020
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort AnalysisAnuradha Jayaram, Anna Wingate, Daniel Wetterskog, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 26, 2024
Characterization of FGFR Alterations and Activation in Patients with High-Risk Non-Muscle-Invasive Bladder CancerJoel R Eisner, Florus C de Jong, Yoichiro Shibata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2016
Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived XenograftsHung-Ming Lam, Ryan McMullin, Holly M Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2021
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic DiseaseMatthew R Smith, Shibu Thomas, Michael Gormley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 26, 2022
Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trialPeter J Hoskin, Kirsten Hopkins, Vivek Misra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 29, 2025
Erdafitinib in Patients with FGFR-altered Advanced or Metastatic CholangiocarcinomaShubham Pant, Joon Oh Park, Wu-Chou Su, et al.
The Lancet. Oncology|October 3, 2021
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 studyFred Saad, Eleni Efstathiou, Gerhardt Attard, et al.
JAMA|December 4, 2019
Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical TrialPeter J Hoskin, Kirsten Hopkins, Vivek Misra, et al.
The Lancet. Oncology|August 4, 2023
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Martin Schuler, Gopa Iyer, et al.
Anti-Cancer Agents in Medicinal Chemistry|August 31, 2012
Selected approaches for rational drug design and high throughput screening to identify anti-cancer moleculesMichael Hedvat, Luni Emdad, Swadesh K Das, et al.
JCO Precision Oncology|September 14, 2020
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort AnalysisAnuradha Jayaram, Anna Wingate, Daniel Wetterskog, et al.
Pageof 5